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Abstract – Leishmaniasis is a vector-borne disease caused by protozoan parasites of the genus Leishmania. Our
knowledge of protein phosphatases (PPs) and their implication in signaling events is very limited. Here we report
the expression, characterization and mutagenesis analysis of a novel protein phosphatase 5 (PP5) in Leishmania major.
Recombinant PP5 is a bona ﬁde phosphatase and is enzymatically active. Site-directed mutagenesis revealed auto-
inhibitory roles of the N-terminal region. This is a rational ﬁrst approach to understand the role of PP5 in the biology
of the parasite better as well as its potential future applicability to anti-parasitic intervention.
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Re´sume´ – Activite´ catalytique d’une nouvelle phosphatase de prote´ine se´rine/thre´onine PP5 de Leishmania
major. La leishmaniose est une maladie transmise par un vecteur, due a` des parasites protozoaires appartenant au
genre Leishmania. Notre connaissance des phosphatases de prote´ines (PPs) et leur implication dans la signalisation
est tre`s limite´e. Nous rapportons ici l’expression, la caracte´risation et les analyses de mutagene`se d’une nouvelle
PP5 chez Leishmania major. La PP5 recombinante est une phosphatase authentique, enzymatiquement active. La
mutagene`se dirige´e a identiﬁe´ les roˆles auto-inhibiteurs de la re´gion N-terminale de la PP5. Il s’agit d’une premie`re
approche rationnelle vers une meilleure compre´hension du roˆle de la PP5 dans la biologie du parasite, ainsi que
pour une utilisation potentielle dans le cadre d’interventions antiparasitaires.
Introduction
Leishmaniasis is a vector-borne disease caused by proto-
zoan parasites of the genus Leishmania [3]. The disease’s med-
ical implications vary from disﬁguring cutaneous leishmaniasis
to life-threatening visceral leishmaniasis. Leishmaniasis is con-
sidered a neglected tropical disease with more than 12 million
people currently infected and approximately 2 million new
cases emerging each year, though these statistics are largely
underestimated due to misdiagnosis and lacking surveillance
systems [2]. Notably, co-infection with the human immunode-
ﬁciency virus (HIV/AIDS) is more detrimental to patients
exhibiting disease, as the infections target similar immune cells
and vastly promote clinical progressions of each other [1].
Though there is no vaccine for leishmaniasis, some treatments
are available and are, usually, species-speciﬁc. Currently the
most common drugs used to treat infection are pentavalent anti-
mony, amphotericin B, and miltefosine. Unfortunately, these
drugs are toxic and expensive. As resistance is a common
feature of most of them, the urge for newer drugs is imperative
[10]. During the infectious cycle, Leishmania differentiates
from the extracellular ﬂagellated promastigote to the intracellu-
lar pathogenic amastigote form. Promastigotes develop in the
midgut of sandﬂies and following infection in humans, differen-
tiate to intracellular amastigotes that multiply inside the macro-
phage lysosome [14]. This differentiation is triggered by
environmental signals, mainly acidic pH and high temperature
in the mammalian host [24]. Signal transduction cascades often
relay these environmental stimuli through reversible phosphor-
ylation via kinases and phosphatases, ultimately leading to
changes in protein activity, interaction and expression proﬁles
[11]. Our knowledge of these signaling molecules in Leish-
mania is scarce despite their essential roles in the biology of
the parasite. Mitogen-activated protein kinases (MAPKs) are
conserved across virtually all eukaryotic organisms. The impor-
tance of the core MAPK pathway has been revealed in
Leishmania mexicana and deletion analysis of LmxMPK1 and
2 showed that both are essential for survival in the amastigote
stage [21, 22]. LmxMPK3 regulates ﬂagellar length [9] and
LmxMKK is the MAPKK responsible for its regulation [23].*Corresponding author: miguel.morales@nd.edu
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On the other hand, our understanding of the biology of protein
phosphatases in trypanosomatids is poor despite the fact that
protein dephosphorylation is largely implicated in critical
post-translational modiﬁcations [15], differentiation [18, 19],
and more recently in parasite drug resistance [4]. Approxi-
mately 96%–99% of proteins in eukaryotes are phosphorylated
on Serine and Threonine (Ser/Thr) residues. Ser/Thr phospha-
tases are divided into three families: phosphoprotein phospha-
tases (PPPs), metallo-dependent protein phosphatases (PPM),
and aspartate-based phosphatases with a DxDxT/V motif
[17]. Protein phosphatase 5 (PP5) is a putative gene belonging
to the PPP family. It has a unique characteristic in that it differs
from other phosphatases in the PPP family due to its N-terminal
tetratricopeptide repeat (TPR) domains, which are momentous
in protein-protein interactions and autoinhibition [5]. In mam-
malian systems, PP5 TPR domains associate with several pro-
teins that affect signal transduction networks, including the
glucocorticoid receptor (GR)-heat shock protein 90 heterocom-
plex [7]. The catalytic domain of PP5 shares 35%–45%
sequence identity with the catalytic domains of other PPP phos-
phatases, including protein phosphatase 1 (PP1), 2A (PP2A),
and 2B/calcineurin. It is less abundant than the above-men-
tioned PPPs in mammalian systems and its basal activity is
low under typical phosphatase assay conditions [8]. Here we
depict the catalytic activity of a novel protein phosphatase
PP5 in L. major and dissect the residues implicated in its
autoinhibitory regulation.
Materials and methods
Bioinformatics
Leishmania major PP5 was used as an initial query for PSI-
BLAST and sequences corresponding to putative PP5 proteins
from the sequenced genomes of Leishmania infantum, L. bra-
ziliensis, L. mexicana, Trypanosoma cruzi, T. brucei, Homo
sapiens, Mus musculus, Arabidopsis thaliana, Bos taurus,
Schistosoma mansoni, and Saccharomyces cerevisae were
retrieved using the TriTrypDB and UniProt databases: (http://
tritrypdb.org/tritrypdb/) and (www.uniprot.org). Sequences
were aligned with Clustal X (v2.0) and edited with Jalview
[20]. Alignments were converted to MEGA compatible ﬁles
and fed into the MEGA5.2 software package. A Neighbor-
Joining tree was computed with 500 bootstrap replicates.
Molecular constructs
In order to generate a recombinant PP5 protein, a 1.4 kb
region containing PP5 was ampliﬁed from genomic DNA of
L. major FV1 using the primers 50-ACC CTC GAG ATG
GAG GAG TCC GAC CGC-30 (XhoI), R 50-GCC GCG
GCC GCT TAA AAT AGA CCC GCG CC-30 (NotI) and
LongAmp high-ﬁdelity Taq-DNA polymerase (New England
Biolabs) following the manufacturer’s recommendation. The
product was cloned into pGEM-T (Promega) to create
pGEM-T-PP5. N-terminal GST-PP5 fusions (Glutathione
S-Transferase) were obtained by inserting the 1.4 kb PP5
fragment from pGEM-T into the respective site of pGEX-5x.
pGEX-5x-PP5 constructs were then transformed in BL-21
Escherichia coli (E. coli) cells (NEB). Cells transfected with
the empty vector, pGEX-5x, were used as mock controls.
Expression and purification
Cell lines were grown in LB broth and ampicillin (100 ug/
mL). At OD = 0.5 the cultures were induced with 0.1 mM iso-
propyl-1-thio-b-D-galactopyranoside (IPTG) for 2 h at room
temperature. Cells were harvested and lysed with BugBuster
(Novagen). Recombinant proteins were puriﬁed with GST-spin
columns (GE Healthcare) as per the manufacturers’ protocol.
Following elution each culture was dialyzed against 50 mM
Tris-HCl (pH 8.0).
Figure 1. Bioinformatics analysis. The relationship of Leishmania
major PP5 (XP_001682421.1) to PP5 homologs of Leishmania
infantum (XP_001464832.1), Leishmania mexicana
(XP_003874029.1), Leishmania braziliensis (XP_001563942.2),
Trypanosoma cruzi (XP_820611.1), Trypanosoma brucei
(XP_827850.1), Arabidopsis thaliana (NP_565985.1), Homo sapi-
ens (NP_006238.1), Mus musculus (NP_035285.2), Bos taurus
(NP_001179178.1), Schistosoma mansoni (XP_002580099.1) and
Saccharomyces cerevisiae (EDN61714.1) was analyzed by multiple
alignment and cluster analysis using Clustal X. Alignment was fed
into MEGA5.2 software and a Neighbor-Joining tree was computed
with 500 bootstrap replicates. Numbers on nodes indicate bootstrap
support.
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Western blotting
Proteins were revealed using the following primary antibod-
ies: rabbit polyclonal anti-GST (Santa Cruz Biotechnology),
rabbit polyclonal anti-PP5 (Abcam) and anti-rabbit HRP-conju-
gated secondary antibodies (Pierce). Cell extracts were sepa-
rated in 4%–12% Bis-Tris NuPAGE gels (Life) and electro-
blotted onto PVDF membranes (Pierce).
Site-directed mutagenesis
GST-PP5 mutants were generated using a QuikChange II
XL Site-Directed Mutagenesis Kit (Agilent Technologies) as
recommended by the manufacturer. Brieﬂy, primers 50-CTC
CCG CGG CAA CGC CGA GGG ACT CTC G-30 and R
50-CGA GAG TCC CTC GGC GTT GCC GCG GGA G-30
were used to create a H276A mutation, primers 50-TAC CTG
AAG CTG GCG CTG CCT GGA GCG-30 and R 50-CGC
TCC AGG CAG CGC CAG CTT CAG GTA-30 were used
to create an E51A mutation and primers 50-CGA CCC TGG
CTT TGT GGC GGC GTA CTA CCG CAA G-30 and R 50-
CTT GCG GTA GTA CGC CGC CAC AAA GCC AGG
GTC G-30 were used to create a K72A mutation.
Biochemical characterization
Activity of L. major recombinant PP5 was measured in a
phosphatase assay using p-nitrophenyl phosphate (pNPP)
(New England Biolabs) as a substrate. Amounts of recombinant
protein were quantiﬁed using a Bradford assay. As GST alone
can alter protein quantiﬁcation, samples were further compared
with known BSA concentrations using densitometry analysis of
a SimplyBlue SafeStain (Invitrogen) stained gel. 1 ug of each
recombinant sample, diluted in 1· colorimetric assay buffer
(20 mM Tris pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.02% b-
mercaptoethanol and 0.1 mg/mL bovine serum albumin
[BSA]), was added to corresponding wells on a 96-well plate
and the reaction was initiated by addition of pNPP. After a
45-min incubation at room temperature, 5N NaOH was added
to each well to stop the reaction. Absorbance (ABS) was read
using a plate reader at 405 nm. Okadaic acid (OA) and arachi-
donic acid (AA) were purchased from Santa Cruz and Sigma,
respectively. Statistical analysis was performed with GraphPad
Prism v. 6.04.
Results and discussion
Using in silico analysis we interrogated the Leishmania
major (L. major) genome for protein phosphatase 5 (PP5)
(XP_001682421). The amino acid sequence of PP5 in L. major
has a 98% overall identity with PP5 from Leishmania infantum
(L. infantum), 77% with Trypanosma cruzi (T. cruzi), 70% with
Trypanosoma brucei (T. brucei), 50% with Arabidopsis
Figure 2. Puriﬁcation of GST-PP5 from BL-21 cells. Cells were
grown to OD = 0.5 and IPTG-induced (0.1 mM) (lanes 1–4) and
uninduced (lanes 5–8) cultures were left to stir for two hours at room
temperature. Protein was extracted and puriﬁed using GST-spin
columns. Lanes are representative of the elution process: total
protein lysate (lanes 1 and 5), ﬂow through washes (lanes 2–3 and
6–7) and GST-PP5 protein eluate (lanes 4 and 8).
Figure 3. Expression of GST-PP5 in BL-21 cells. Expression of
GST-PP5 as detected by Western blotting using an anti-GST
antibody (left panel) induced with 0.1 mM IPTG or uninduced.
Right panel, polyclonal anti-PP5 antibody. Lanes are representative
of the elution process: total protein lysate (lane 1), ﬂow through
washes (lanes 2 and 3) and GST-PP5 protein eluate (lane 4). The
molecular weight of standard proteins is indicated in kDa.
Figure 4. Catalytic activity. PP5 activity was assessed at increasing
pNPP substrate concentrations [d] in the presence of 5 lM AA [m]
or 25 lM OA [n] and absorbance was measured on a plate reader at
405 nm. A dose-dependent non-linear regression curve was gener-
ated and standard deviation is shown (n = 3).
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thaliana (A. thaliana) and only 46% with Schistosoma mansoni
(S. mansoni), Mus musculus (M. musculus), and Homo sapiens
(H. sapiens). L. major PP5 contains three distinct TPR motifs
with lower homology to its mammalian counterparts
(Fig. S1). Clustering analysis based on multiple alignment con-
ﬁrmed that L. major PP5 is closely related to other trypanoso-
matid PP5s (Fig. 1).
In order to biochemically characterize PP5 we generated a
recombinant GST-PP5 fusion protein which was expressed in
BL21 E. coli cells. GST-PP5 expression was increased in
IPTG-induced cultures as observed by Coomassie staining
(Fig. 2, lanes 4 and 8) and Western blot (Fig. 3, left panel) using
a rabbit polyclonal anti-GST antibody. To further test the spec-
iﬁcity of GST puriﬁcation, eluted recombinant proteins were
separated, electro-blotted onto PVDF membranes and detected
with a polyclonal anti-PP5 antibody (Fig. 3, right panel). Prior
to performing the activity assay, a gel was run and stained with
Coomassie to compare each sample with BSA loading controls
via densitometry (Fig. S2-B). This ensured the use of proper
amounts of sample for the activity assay, as GST alone could
alter protein quantiﬁcation (Fig. S2-A).
Being the ﬁrst description of PP5 in L. major, we measured
the catalytic activity of PP5 using increasing concentrations of
p-nitrophenyl phosphate (pNPP) as a substrate. A dose-depen-
dent non-linear regression curve was plotted for the activity of
PP5 and PP5 in the presence of 5 lM arachidonic acid (AA)
and 25 lM okadaic acid (OA), a generic phosphatase inhibitor
(Fig. 4). L. major recombinant PP5 is enzymatically active and
is inhibited in the presence of OA. Polyunsaturated fatty acids
such as AA interact with the TPR domain of PP5, thus activat-
ing the enzyme. Our results are in good accordance with the
activation of T. brucei PP5 in the presence of AA and the reg-
ulatory effect of the TPR domain on enzymatic activity [6].
As mentioned above, the TPR domain on the N-terminal
end of PP5 has a known autoinhibitory function [16], therefore
we performed site-directed mutagenesis to test the potential
negative regulation of a glutamic acid residue (E51A) previ-
ously analyzed in mammalian systems [13]. We also mutated
a lysine (K72A) residue known to bind to HSP90 [13] and a
histidine (H276A) residue known to positively regulate the
activity of PP5 [5] (Fig. 5). L. major PP5 is active in the
Figure 5. PP5 structure. Leishmania PP5 contains a TPR domain made of three TPRs (red) and one phosphatase catalytic domain (blue). Site-
directed mutagenesis was performed to change Histidine to Alanine at position 276 [H276A], Lysine to Alanine at position 72 [K72A], and
Glutamic Acid to Alanine at position 51 [E51A].
Figure 6. Biochemical characterization of GST-PP5 mutants. Phos-
phatase activity was assessed at two different pNPP substrate
concentrations simultaneously (5 mM and 12.5 mM, respectively)
and absorbance was measured on a plate reader at 405 nm. Standard
deviation is denoted by the bars shown (n = 3).
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presence of 5 mM and 12.5 mM pNPP. 25 lMOAwas used as
a negative control, although complete inhibition was not
observed. Glutathione S-Transferase (GST) was assayed as a
negative and background control (Fig. 6). H276A mutation
on the C-terminal abolishes PP5 activity in good accordance
with its mammalian counterpart [5]. As expected, E51A muta-
tion on the TPR domain results in signiﬁcantly increased activ-
ity, regardless of the different pNPP concentrations assayed,
suggesting a potential inhibitory role. K72A mutation, which
is part of the HSP90-binding groove in the TPR domain [13],
has no regulatory function in the catalytic activity of L. major
PP5. Together these results suggest that L. major PP5 is active
and is a bona ﬁde phosphatase.
The autoinhibitory function of the TPR domain is con-
served in Leishmania and we found Glu51 to be implicated
in this regulation. On the other hand, Lys72 does not negatively
regulate the catalytic activity of PP5; however, further studies
using endogenous PP5 parasite extracts are necessary to reveal
its implication in the potential interaction with HSP90. Protein
binding assays with immunoprecipitated recombinant GST-PP5
and total extracts of L. major did not reveal interaction with
HSP90 (data not shown). It is important to note that our inabil-
ity to reveal a PP5- HSP90 interaction may be due to the steric
hindrance of GST fused N-terminally to PP5, where the TPR
domain is located. Thus, we can only speculate that endogenous
L. major PP5 may interact with HSP90. Additionally, it has
been shown previously in the related T. brucei that PP5 interacts
with and is required to regulate HSP90 function under stress
conditions [12].
Conclusions
The complete genomes of trypanosomatids (www.
trytrip.org) have made possible the screening of putative protein
phosphatases. The biochemical characterization of this novel
PP5 in Leishmania major is a rational ﬁrst approach to further
understand the regulation of signal transduction pathways in
this parasite. Additional studies are required to assess substrate
speciﬁcity and in vivo function. Nonetheless, L. major PP5
shows low similarity with its mammalian counterparts, suggest-
ing it may be targeted for therapeutic intervention.
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